Antiaggregants in cardiology: choice of best individual treatment
https://doi.org/10.21518/2079-701X-2015-12-34-43
Abstract
The role of antithrombotic therapy in cardiology has increased substantially over the past decades. On the one hand, mortality causes monitoring, undertaken by certain countries as wellas on the global level under the auspices of the World Health Organization, demonstrate the leading role of thrombosis as a pathogenetic mechanism underlying the majority of premature deaths. The role of this mechanism is revealed by the excellent words of Jens Dedichen (1959): "Man lives with arteriosclerosis, and dies of the complicating thrombosis." [1] On the other hand, the widespread use of antithrombotic therapy is associated not only with the need to prevent both primary and, largely, recurring cardiovascular events, but also with a spread of minimally invasive revascularization techniques. Enovascular interventions the number of which has rapidly grown in in Russia over the past years, became a truly effective and safe treatment thanks to the present-day antithrombotic therapy.
About the Author
A. N. Yakovlev
Almazov Federal North-West Medical Research Centre, Ministry of Health of the Russian Federation, St. Petersburg
Russian Federation
Russian Federation
References
1. Dedichen J. Thrombosing atherosclerosis. Result of long-term anticoagulant therapy. Brit Med J, 1956, 11: 1038-1039.
2. Garg VP, Halperin JL, Novel Antiplatelet and Anticoagulant Agents in the Cardiac Care Unit. Cardiol Clin, 31 (2013) 533-544.
3. Mega JL, Simon T: Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet, 386: 281-291, 2015
4. ISIS2 (Second International Study of Infarct Survival) Collaborative Group : Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected myocardial infarction. Lancet, 1988, 2: 349-360.
5. Sabatine MS, Cannon CP, Gibson CM, et al: Addition of clopidogrel to aspirin and fibrino-lytic therapy for myocardial infarction with ST segment elevation. N Engl J Med, 2005, 352: 1179-1182.
6. Lewis HD, Davis JW, Archibald DG, et al: Protective effects of aspirin against acute myo-cardial infarction and death in men with unstable angina. Results of a Veterans Administration cooperative study. N Engl J Med, 1983, 309: 396-403.
7. Research Group on Instability in Coronary Artery Disease (RISC) Investigators: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet, 1990, 336: 827-830.
8. Savage MP, Goldberg S, Bove AA, et al: Effect of thromboxane A. Circulation, 1995, 92: 31943200.
9. Goldman S, Copeland J, Moritz T, et al: Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of anti-platelet therapy. Results of a Veterans Administration cooperative study. Circulation, 1989, 80: 1190-1197.
10. Gavaghan TP, Gebski V, and Baron DW: Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation, 1991, 83: 1526-1533.
11. Antithrombotic Trialists' Collaboration : Collaborative metaanalysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002, 324: 71-86.
12. Antithrombotic Trialists' Collaboration : Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet, 2009, 373: 1849-1860.
13. Becattini C, Agnelli G, Schenone, et al. Aspirin for preventing the recurrence of venous thrombo-embolism. N Engl J Med, 2012, 366: 1959-1967.
14. Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med, 2012, 367: 1979-1987.
15. Patrono C: Aspirin as an antiplatelet drug. N E6ngl J Med, 1994, 330: 1287-1294.
16. Serebruany VL, Steinhubl SR, Berger PB, et al: Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol, 2005, 95: 1218-1222.
17. Windecker S, Kolh P,Alfonso F et al. 2014 ESC/ EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.
18. Gent M, Donald Easton J, Hachinski VC, et al: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet, 1989, 333: 1215-1220.
19. Janzon L, Bergqvist J, Bober J, et al: Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlo-pidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med, 1990, 227: 301-308.
20. Leon MB, Baim DS, Popma JJ, et al: A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting. N Engl J Med, 1998, 339: 1665-1671.
21. Яковлев А.Н. Применение воспроизведенных форм клопидогрела в лечении пациентов с острым коронарным синдромом: все ли вопросы решены? Медицинский совет, 2014, 12: 40-43.
22. Mega JL, Close SL, Wiviott SD, et al: Cyto-chrome P450 polymorphisms and response to clopidogrel. N Engl J Med, 2009, 360: 354-362.
23. Caplain H, Thebault JJ, and Necciari J: Clopidogrel does not affect the pharmacoki-netics of theophylline. Semin Thromb Hemost, 1999, 25: 65-68.
24. Hochholzer W, Trenk D, Frundi D, et al: Time dependence of platelet inhibition after a 600mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation, 2005, 111: 2560-2564.
25. CAPRIE Steering Committee : A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996, 348: 1329-1339.
Review
For citations:
Yakovlev AN. Antiaggregants in cardiology: choice of best individual treatment. Meditsinskiy sovet = Medical Council. 2015;(12):34-43. (In Russ.) https://doi.org/10.21518/2079-701X-2015-12-34-43
Views:
467
Email this article 